Alnylam Pharmaceuticals, Inc. (ALNY)

Pharmaceutical Preparations

Latest Price

$246.74

TTM P/E

Normalized P/E

Div Yield

Book Value

10.16

P/B Ratio

24.28

Valuation metrics

EPS: $2.33

Book value / share: $5.96

Formula: √(22.5 × EPS × BVPS)

Graham Number

$17.68

93% downside

Base FCF: $254M (median of recent 5yr)

Growth: 5%/yr (median YOY, capped at 25%)

Discount rate: 10%

Terminal growth: 3%

Projection horizon: 10 years

DCF Fair Value

$45.20

82% downside

EPS: $2.33

Target P/E: 15×

Formula: EPS × P/E

P/E Fair Value

$34.95

86% downside

100.0% held by institutions

Institution	Shares	Value	Ownership %	Change	Filing Date
FMR LLC	15.02M	$4.52B	11.23%	+444.8K	2026-06-30
Capital World Investors	11.14M	$3.35B	8.33%	+342.5K	2026-06-30
BlackRock, Inc.	10.91M	$3.28B	8.16%	+462.8K	2026-06-30
Capital Research Global Investors	9.75M	$2.94B	7.29%	+279.5K	2026-06-30
Vanguard Portfolio Management LLC	6.54M	$1.97B	4.89%	+47.1K	2026-06-30
Vanguard Capital Management LLC	6.03M	$1.81B	4.51%	+82.8K	2026-06-30
T. Rowe Price Investment Management, Inc.	5.64M	$1.70B	4.22%	+448.8K	2026-06-30
Invesco Ltd.	3.75M	$1.13B	2.81%	+2.46M	2026-06-30
State Street Corp	3.56M	$1.07B	2.66%	+233.0K	2026-06-30
JPMorgan Chase & Co	2.68M	$785.0M	2.00%	-2.04M	2026-06-30